Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
Positive:
Very strong bullish trend, it is expecting a price correction after this stock should follow
Positive:
- Yields high return on invested capital
- Has raised its dividend for 8 consecutive years
- 13 analysts have revised their earnings upwards for the upcoming period
- Prominent player in the Pharmaceuticals industry
- Cash flows can sufficiently cover interest payments
- High return over the last year
- An analyst from Morgan Stanley maintained Eli Lilly (NYSE: LLY) at 'overweight' with a price target of $640.00 from a prior price target of $617.00.
- Trading at a high earnings multiple
- Corporate insiders Sold shares worth $21.3B in the past 3 months
- Hedge funds Sold 789.5K shares in the past quarter
-
Very strong bullish trend, it is expecting a price correction after this stock should follow